The immunological challenge to developing a vaccine to the blood stages of malaria parasites
- PMID: 15361246
- DOI: 10.1111/j.0105-2896.2004.00178.x
The immunological challenge to developing a vaccine to the blood stages of malaria parasites
Abstract
Twenty-one years after malaria antigens were first cloned, a vaccine still appears to be a long way off. There have been periods of great excitement, and in model systems, subunit vaccine homologs can induce robust protection. However, significant challenges exist concerning antigenic variation and polymorphism, immunological non-responsiveness to individual vaccine antigens, parasite-induced apoptosis of immune effector and memory cells, and immune deviation as a result of maternal immunity and alterations of dendritic cell function. Novel approaches will be required. This review addresses some of the approaches that might present malaria antigens in a way designed to induce superior immune responses or that target novel conserved epitopes. Cell-mediated immunity, acting independently of antibody, may exert potent anti-parasite effects, and identification of multiple target antigens/epitopes could lead to the development of vaccines with profound efficacy.
Similar articles
-
Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.Acc Chem Res. 2008 Mar;41(3):377-86. doi: 10.1021/ar700120t. Epub 2008 Feb 12. Acc Chem Res. 2008. PMID: 18266328 Review.
-
Vaccine-induced immunity to malaria parasites and the need for novel strategies.Trends Parasitol. 2005 Jan;21(1):29-34. doi: 10.1016/j.pt.2004.10.006. Trends Parasitol. 2005. PMID: 15639738 Review.
-
The hope but challenge for developing a vaccine that might control malaria.Eur J Immunol. 2009 Apr;39(4):939-43. doi: 10.1002/eji.200939390. Eur J Immunol. 2009. PMID: 19350585
-
Immune effector mechanisms in malaria.Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60. doi: 10.1111/j.1365-3024.2006.00808.x. Parasite Immunol. 2006. PMID: 16438676 Review.
-
A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.Infect Immun. 2004 Oct;72(10):5565-73. doi: 10.1128/IAI.72.10.5565-5573.2004. Infect Immun. 2004. PMID: 15385453 Free PMC article.
Cited by
-
The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design.Front Immunol. 2020 Feb 27;11:335. doi: 10.3389/fimmu.2020.00335. eCollection 2020. Front Immunol. 2020. PMID: 32174924 Free PMC article. Review.
-
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.PLoS One. 2008;3(10):e3571. doi: 10.1371/journal.pone.0003571. Epub 2008 Oct 29. PLoS One. 2008. PMID: 18958278 Free PMC article.
-
High-Level Expression of Immunogenic Recombinant Plasmodium vivax Merozoite Surface Protein (Pvmsp-142 kDa) in pGEX 6P1 Vector.Iran J Public Health. 2015 Jan;44(1):89-99. Iran J Public Health. 2015. PMID: 26060780 Free PMC article.
-
Opsonization of malaria-infected erythrocytes activates the inflammasome and enhances inflammatory cytokine secretion by human macrophages.Malar J. 2012 Oct 9;11:343. doi: 10.1186/1475-2875-11-343. Malar J. 2012. PMID: 23046548 Free PMC article.
-
Characterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparum.Infect Immun. 2008 Mar;76(3):879-87. doi: 10.1128/IAI.00144-07. Epub 2008 Jan 3. Infect Immun. 2008. PMID: 18174339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
